LL-37

LL-37 is a 37-amino acid cationic host defense peptide that represents the only member of the cathelicidin family in humans. It is the active form derived from the precursor protein hCAP18 (human cationic antimicrobial protein 18), which is cleaved extracellularly to release the active LL-37 fragment. The name reflects its two N-terminal leucines followed by a 37-amino acid sequence.

LL-37 is produced by neutrophils, monocytes/macrophages, NK cells, mast cells, and epithelial cells throughout the body — particularly in the skin, respiratory tract, gut, and urogenital tract. It serves as a first-line defense against bacterial, viral, and fungal pathogens while also acting as a signaling molecule that modulates both innate and adaptive immune responses.

Beyond its antimicrobial role, LL-37 has attracted research interest for its tissue healing properties. It promotes wound closure, angiogenesis, and re-epithelialization, making it relevant to the healing and recovery peptide category despite being primarily an immune peptide.

LL-37 is not FDA-approved for any therapeutic use in humans. Research applications and clinical investigations are ongoing.

LL-37 operates through multiple distinct mechanisms:

• Membrane disruption: As a cationic amphipathic peptide, LL-37 is electrostatically attracted to negatively charged bacterial membranes. It inserts into and disrupts lipid bilayers of bacteria, fungi, and some enveloped viruses, causing membrane permeabilization and cell death — a mechanism that is difficult for pathogens to develop resistance against.
• Biofilm disruption: LL-37 inhibits biofilm formation and can disrupt established biofilms by interacting with extracellular DNA (eDNA), which serves as a structural scaffold for many biofilms.
• Immunomodulation: LL-37 acts as a chemokine receptor ligand (notably for FPRL1/FPR2) and modulates TLR signaling, promoting selective activation or dampening of inflammatory responses depending on context.
• Wound healing promotion: LL-37 activates epidermal growth factor receptor (EGFR) signaling and stimulates keratinocyte migration and proliferation. It also promotes angiogenesis through VEGF upregulation.
• Neutrophil and monocyte recruitment: LL-37 acts as a chemoattractant for immune cells, coordinating the early cellular response to infection or injury.
• Apoptosis modulation: Depending on concentration and cellular context, LL-37 can both promote and inhibit apoptosis, with potential roles in both immune cell lifespan and cancer biology.

Research into LL-37 has identified potential benefits across several domains:

• Antimicrobial defense: LL-37 is active against a broad spectrum of gram-positive and gram-negative bacteria, many antibiotic-resistant strains, fungi, and some viruses. This makes it particularly interesting in the context of antimicrobial resistance.
• Wound healing: LL-37 accelerates wound closure in animal models and in vitro studies through keratinocyte migration, proliferation, and EGFR activation. Clinical interest includes chronic wound applications.
• Biofilm prevention: Biofilms dramatically increase antibiotic resistance. LL-37's ability to prevent and disrupt biofilms offers a potential strategy against chronic infections (e.g., in diabetic wounds, respiratory infections).
• Anti-viral activity: Research has shown activity against HIV, herpes simplex virus, respiratory syncytial virus (RSV), and influenza, partly through direct membrane disruption and partly through antiviral immune signaling.
• Anti-cancer properties: Some studies suggest LL-37 may suppress tumor growth, though paradoxically other studies link high LL-37 expression to some cancer types. This dual role requires careful interpretation.
• Lung health: LL-37 is studied in the context of cystic fibrosis and chronic obstructive pulmonary disease (COPD), where impaired cathelicidin production may contribute to chronic lung infections.

LL-37 has a complex safety profile that differs meaningfully from typical research peptides. Important considerations include:

• Cytotoxicity at high concentrations: At elevated concentrations, LL-37 can disrupt mammalian cell membranes in addition to bacterial membranes. The therapeutic window — the range between effective antimicrobial/healing doses and cytotoxic doses — is an important safety consideration.
• Pro-inflammatory effects: While LL-37 can dampen some inflammatory pathways, at higher doses it may stimulate excessive inflammatory responses through TLR activation and cytokine release.
• Potential cancer-related concerns: Given its complex and sometimes opposing effects on cell proliferation and apoptosis, the role of exogenous LL-37 in cancer contexts is unclear and warrants caution.
• Injection site reactions: Subcutaneous administration may cause local inflammation given LL-37's immune cell recruitment properties.
• Autoimmune implications: Elevated LL-37 has been linked to autoimmune conditions including psoriasis, rheumatoid arthritis, and lupus through formation of immune-activating complexes with self-DNA.

The safety profile of systemic injectable LL-37 in healthy humans has not been adequately characterized in clinical trials.

Disclaimer: LL-37 is not FDA-approved for human use. The following is for educational reference only, derived from research literature.

Unlike peptides such as BPC-157 or TB-500 that have relatively consistent anecdotal dosing frameworks, LL-37 has a less established human dosing convention, in part because of its complex dose-dependent effects:

• Research context: In vitro studies use concentrations typically in the range of 1–50 µg/mL; in vivo animal studies use a wide range of doses
• Topical formulations: Some preclinical and early clinical research has explored topical LL-37 creams for wound healing, where local concentration can be better controlled
• Systemic injectable use: Not well characterized in human research; extreme caution is warranted due to the potential for systemic inflammatory activation

Given its complex immunomodulatory profile, LL-37 carries more uncertainty regarding appropriate human dosing than most other research peptides. Medical supervision is strongly recommended.

LL-37 research is extensive and covers several biomedical domains:

• Antimicrobial resistance: With the growing crisis of antibiotic resistance, LL-37 and other host defense peptides (HDPs) are being studied as novel antimicrobial agents. Key advantages include activity against multi-drug resistant organisms and a low propensity for resistance development.
• Wound healing: Research groups have demonstrated LL-37's ability to accelerate wound closure in diabetic mouse models, which are notoriously slow-healing. This has motivated clinical interest in chronic diabetic wound applications.
• Cystic fibrosis: The salty, dehydrated airway surface liquid in CF lungs inactivates LL-37 and other defensins, contributing to the chronic lung infections that define this disease. Strategies to restore antimicrobial peptide activity in CF airways are an active area of research.
• Skin diseases: The paradoxical role of LL-37 — protective in infections but potentially pathogenic in autoimmune skin disease — has been extensively studied in psoriasis, where LL-37-DNA complexes activate plasmacytoid dendritic cells via TLR9.
• COVID-19 connection: During the COVID-19 pandemic, several research groups explored whether vitamin D-stimulated LL-37 production might contribute to immune protection, as LL-37 gene expression is induced by vitamin D signaling.